Cyberonics to Host Investor and Analyst Meeting in Boston

Wednesday, November 11, 2009 General News J E 4
HOUSTON, Nov. 10 Cyberonics, Inc. (Nasdaq: CYBX) today announced it will host an investor and analyst meeting on Friday, December 4, 2009 at the Westin Copley Place in Boston, Massachusetts. The meeting, which also will be webcast live, will begin at 9:00 a.m. eastern time and end at approximately 12:30 p.m. eastern time.

Presentations on current epilepsy treatments, VNS Therapy(TM) and the future role that medical devices will play in addressing the needs of patients with epilepsy will be made by:

In addition, presentations on Cyberonics' development priorities and timelines, U.S. and International market potential and replacement trends will be made by:

Institutional investors and analysts interested in attending the investor and analyst meeting should contact Jackie Baumgartner at 1-281-228-7229 or

This meeting will be webcast live and by replay and will include the slides from the meeting. To access the webcast, please enter the Company's website at, then follow the webcast link listed under Recent Presentations.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (Nasdaq: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at and

-- Angus Wilfong, M.D., Associate Professor, Pediatrics and Neurology, Baylor College of Medicine; Medical Director, Comprehensive Epilepsy Program, Texas Children's Hospital; and -- Steven Karceski, M.D., Associate Clinical Professor of Neurology, College of Physicians and Surgeons, Columbia University.

SOURCE Cyberonics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Cardium Reports on Third Quarter 2009 Financial Re...
Pfizer, BMP Sunstone Announce Collaboration on Wom...